Sobi appoints Philip Wood Vice President and Commercial Therapeutic Area Head Haemophilia
(Thomson Reuters ONE) -
Swedish Orphan Biovitrum AB (publ) (Sobi) today announced that Philip Wood has
been appointed Vice President and Commercial Therapeutic Area Head Haemophilia.
Philip Wood joined Sobi in March 2012 as the Global Strategic Lead for the
company's Haemophilia A team, focusing on the pre-launch platform for the
potential Factor VIII product. Prior to joining Sobi, Wood worked for both Wyeth
and Pfizer in various positions of increasing responsibility from sales
representative to European Director and European Specialty Asset Team Leader
where he was responsible for the UK and then European re-launch of ReFacto® and
Benefix®.
"Philip brings significant launch and commercialization experience from the
Haemophilia field to this role, and we are pleased that he will bring an
integrated cross-functional approach to what we expect to be our most important
program in the coming years", said Alan Raffensperger, COO.
Together with its partner Biogen Idec, Sobi currently has two on-going
paediatric phase III trials, KIDS A-LONG and KIDS B-LONG in addition to the on-
going open label extension studies from the adult phase 3 trials. Sobi expects
to release top line data from these trials during 2014.
---
About Sobi
Sobi is an international specialty healthcare company dedicated to rare
diseases. Our mission is to develop and deliver innovative therapies and
services to improve the lives of patients. The product portfolio is primarily
focused on inflammation and genetic diseases, with three late stage biological
development projects within haemophilia and neonatology. We also market a
portfolio of specialty and rare disease products for partner companies. Sobi is
a pioneer in biotechnology with world-class capabilities in protein biochemistry
and biologics manufacturing. In 2012, Sobi had total revenues of SEK 1.9 billion
(? 215 M) and about 500 employees. The share (STO: SOBI) is listed on NASDAQ OMX
Stockholm. More information is available at www.sobi.com
For more information - not for publication
Media relations Investor relations
Oskar Bosson, Head of Jörgen Winroth, Vice President, Head of Investor
Communications Relations
T: +46 70 410 71 80 T: +1 347-224-0819, +1 212-579-0506, +46 8 697 2135
oskar.bosson(at)sobi.com jorgen.winroth(at)sobi.com
Sobi appoints Philip Wood:
http://hugin.info/134557/R/1742275/585661.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Swedish Orphan Biovitrum AB (publ) via Thomson Reuters ONE
[HUG#1742275]
Unternehmensinformation / Kurzprofil:
Datum: 12.11.2013 - 08:00 Uhr
Sprache: Deutsch
News-ID 315180
Anzahl Zeichen: 3265
contact information:
Town:
Stockholm
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 147 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Sobi appoints Philip Wood Vice President and Commercial Therapeutic Area Head Haemophilia"
steht unter der journalistisch-redaktionellen Verantwortung von
Swedish Orphan Biovitrum AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
